Immediate Impact

7 by Nobel laureates 55 standout
Sub-graph 1 of 21

Citing Papers

The anti-PD-L1/CTLA-4 bispecific antibody KN046 plus lenvatinib in advanced unresectable or metastatic hepatocellular carcinoma: a phase II trial
2025 Standout
A covalent peptide-based lysosome-targeting protein degradation platform for cancer immunotherapy
2025 Standout
2 intermediate papers

Works of Ruixin Li being referenced

Epigenetically silenced PD-L1 confers drug resistance to anti-PD1 therapy in gastric cardia adenocarcinoma
2020

Author Peers

Author Last Decade Papers Cites
Ruixin Li 244 84 268 239 129 1.2k
Takashi Saito 255 106 235 83 68 1.0k
Kenichi Iwasaki 174 103 325 65 89 1.1k
Xiaofeng Shan 357 66 198 104 110 1.1k
Yabing Wang 158 186 200 60 96 1.2k
T Matsumura 202 33 441 53 109 1.2k
Kwang Ho Cho 261 94 304 133 129 1.5k
Kenji Hara 647 15 438 60 61 1.7k
Jun Lee 263 58 364 68 71 1.6k
Chunbo Li 290 44 354 96 63 1.3k
Kenji Satô 287 62 288 144 98 1.2k

All Works

Loading papers...

Rankless by CCL
2026